Gilead Sciences, Inc. turned to the National Advertising Division rather than the US Food and Drug Administration when it sought action against ViiV Healthcare’s Dovato HIV drug advertising claims. But ViiV declined to participate in NAD’s review so NAD has referred the matter to both FDA and the Federal Trade Commission.
ViiV Wants FDA, Not NAD, To Handle Dispute Over Its Dovato HIV Drug Ads
National Advertising Division refers Gilead’s challenge of ViiV’s advertisements to the FDA and FTC after ViiV declines to participate in its review. Gilead says the ads claim Dovato is superior to its HIV drug Biktarvy, while ViiV suggests a review would amount to second-guessing the FDA.
